Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2

References

• FagioliniAAlfonsiEAmodeoGSwitching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatristsExpert Opin Drug Saf201615444945526886162
   PubMed Web of Science ®Google Scholar
• YathamLNKennedySHParikhSVCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013Bipolar Disord201315114423237061
   PubMed Web of Science ®Google Scholar
• MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935
   PubMed Web of Science ®Google Scholar
• VelliganDIWeidenPJSajatovicMExpert Consensus Panel on Adherence Problems in Serious and Persistent Mental IllnessThe expert consensus guideline series: adherence problems in patients with serious and persistent mental illnessJ Clin Psychiatry200970suppl 4146474819686636
   PubMed Web of Science ®Google Scholar
• HudsonTJOwenRRThrushCRA pilot study of barriers to medication adherence in schizophreniaJ Clin Psychiatry200465221121615003075
   PubMed Web of Science ®Google Scholar
• KaneJMEerdekensMLindenmayerJPKeithSJLesemMKarcherKLong-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry200316061125113212777271
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUNon-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry201312321622624096780
   PubMed Web of Science ®Google Scholar
• CorrellCUCitromeLHaddadPMThe use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidenceJ Clin Psychiatry201677suppl 312427732772
   PubMed Web of Science ®Google Scholar
• BrissosSVeguillaMRTaylorDBalanza-MartinezVThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisalTher Adv Psychopharmacol20144519821925360245
   PubMedGoogle Scholar
• GiganteADLaferBYathamLNLong-acting injectable antipsychotics for the maintenance treatment of bipolar disorderCNS Drugs201226540342022494448
   PubMed Web of Science ®Google Scholar
• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand2007115426026717355516
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull201440119221323256986
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUAssessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryJ Clin Epidemiol2013668 supplS37S4123849151
   PubMed Web of Science ®Google Scholar
• KishimotoTHagiKNittaMEffectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studiesSchizophr Bull201844360361929868849
   PubMed Web of Science ®Google Scholar
• ChouYHChuPCWuSWA systemic review and experts’ consensus for long-acting injectable antipsychotics in bipolar disorderClin Psychopharmacol Neurosci201513212112826243837
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association; Steering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 suppl156
   PubMed Web of Science ®Google Scholar
• LlorcaPMAbbarMCourtetPGuillaumeSLancrenonSSamalinLGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illnessBMC Psychiatry20131334024359031
   PubMed Web of Science ®Google Scholar
• BrookRHChassinMRFinkASolomonDHKosecoffJParkREA method for the detailed assessment of the appropriateness of medical technologiesInt J Technol Assess Health Care198621536310300718
   PubMedGoogle Scholar
• WeidenPJPreskornSHFahnestockPARoadmap SurveyTranslating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmapJ Clin Psychiatry200768suppl 714817650057
   PubMed Web of Science ®Google Scholar
• WeidenPRapkinBZygmuntAMottTGoldmanDFrancesAPostdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimenPsychiatr Serv19954610104910548829787
   PubMed Web of Science ®Google Scholar
• De HertMDekkerJMWoodDKahlKGHoltRIMollerHJCardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)Eur Psychiatry200924641242419682863
   PubMed Web of Science ®Google Scholar
• NgFMammenOKWiltingIInternational Society for Bipolar DisordersThe International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatmentsBipolar Disord200911655959519689501
   PubMed Web of Science ®Google Scholar
• AlphsLMaoLLynn StarrHBensonCA pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophreniaSchizophr Res20161702–325926426742509
   PubMed Web of Science ®Google Scholar
• SchreinerAAadamsooKAltamuraACPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophreniaSchizophr Res20151691–339339926431793
   PubMed Web of Science ®Google Scholar
• SubotnikKLCasausLRVenturaJLong-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trialJAMA Psychiatry201572882282926107752
   PubMed Web of Science ®Google Scholar
• WeidenPJRomaRSVelliganDIAlphsLDiChiaraMDavidsonBThe challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophreniaJ Clin Psychiatry201576668469025939027
   PubMed Web of Science ®Google Scholar
• SacchettiEGrunzeHLeuchtSVitaALong-acting injection antipsychotic medications in the management of schizophreniaEvid Based Psychiatr Care201512736
   Google Scholar
• National Institute for Health and Care Excellence (NICL)Psychosis and Schizophrenia in Adults: Treatment and ManagementLondon, UKNational Institute for Health and Care Excellence (NICL)2014
   Google Scholar
• GoodwinGMHaddadPMFerrierINEvidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for PsychopharmacologyJ Psychopharmacol201630649555326979387
   PubMed Web of Science ®Google Scholar
• KetterTAAcute and maintenance treatments for bipolar depressionJ Clin Psychiatry2014754e1024813411
   PubMedGoogle Scholar
• TaylorDMCorneliusVSmithLYoungAHComparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysisActa Psychiatr Scand2014130645246925283309
   PubMed Web of Science ®Google Scholar
• CalabreseJRSanchezRJinNEfficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal studyJ Clin Psychiatry201778332433128146613
   PubMed Web of Science ®Google Scholar
• VietaEMontgomerySSulaimanAHA randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorderEur Neuropsychopharmacol2012221182583522503488
   PubMed Web of Science ®Google Scholar
• QuirozJAYathamLNPalumboJMKarcherKKushnerSKusumakarVRisperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorderBiol Psychiatry201068215616220227682
   PubMed Web of Science ®Google Scholar
• KaneJMCorrellCUThe role of clozapine in treatment-resistant schizophreniaJAMA Psychiatry201673318718826841681
   PubMed Web of Science ®Google Scholar
• StroupTSGerhardTCrystalSHuangCOlfsonMGeographic and clinical variation in clozapine use in the United StatesPsychiatr Serv201465218619224233347
   PubMed Web of Science ®Google Scholar
• CorrellCURubioJMInczedy-FarkasGBirnbaumMLKaneJMLeuchtSEfficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidenceJAMA Psychiatry201774767568428514486
   PubMed Web of Science ®Google Scholar
• OstacherMJTandonRSuppesTFlorida best practice psychotherapeutic medication guidelines for adults with bipolar disorder: a novel, practical, patient-centered guide for cliniciansJ Clin Psychiatry201677792092626580001
   PubMed Web of Science ®Google Scholar
• GallingBRoldanAHagiKAntipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysisWorld Psychiatry2017161778928127934
   PubMed Web of Science ®Google Scholar
• LeuchtSLeuchtCHuhnMSixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictorsAm J Psychiatry20171741092794228541090
   PubMed Web of Science ®Google Scholar
• MalhiGSMorrisGHamiltonAOuthredTDasPDefining the role of SGAs in the long-term treatment of bipolar disorderBipolar Disord2017191656728346768
   PubMed Web of Science ®Google Scholar
• HowesODMcCutcheonRAgidOTreatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminologyAm J Psychiatry2017174321622927919182
   PubMed Web of Science ®Google Scholar
• MisawaFKishimotoTHagiKKaneJMCorrellCUSafety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychoticsSchizophr Res20161762–322023027499361
   PubMed Web of Science ®Google Scholar
• KaneJMLeuchtSCarpenterDDochertyJPExpert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJ Clin Psychiatry200364suppl 12519
   PubMed Web of Science ®Google Scholar
• McEvoyJPThe expert consensus guidelines series: treatment of schizophreniaJ Clin Psychiatry199960suppl 11180
   Google Scholar
• KeckPEPerlisRHOttoMWCarpenterDDochertyJPRossRThe expert consensus guideline series: treatment of bipolar disorder 2004Postgrad Med Spec Rep20041116
   Google Scholar
• SajatovicMRossRLegacySNInitiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder–expert consensus survey part 1Neuropsychiatr Dis Treat2018
   Web of Science ®Google Scholar